Lebenslauf - Max-Planck-Institut für Kolloid

Lebenslauf
Persönliche Daten:
Name:
Dr. Bernd Lepenies
Anschrift:
Max-Planck-Institut für Kolloid- und
Grenzflächenforschung
Abteilung für Biomolekulare Systeme
Arnimallee 22, 14195 Berlin
Tel.: 030/838-59572
Fax: 030/838-59302
Email: [email protected]
Geburtsdatum, -ort: 18.09.1978 in Hameln
Staatsangehörigkeit: deutsch
Familienstand:
verheiratet, zwei Söhne
Wissenschaftlicher und beruflicher Werdegang:
seit 02/2009
Gruppenleiter (BMBF-Nachwuchsgruppe „Glykobiotechnologie“) am MaxPlanck-Institut für Kolloid- und Grenzflächenforschung, Potsdam
01/2008 – 01/2009
Postdoktorand im Laboratorium für Organische Chemie, ETH Zürich,
Schweiz, in der Arbeitsgruppe von Prof. Dr. Peter H. Seeberger
Ausbildung:
12/2007
Promotion zum Dr. rer. nat. (Biologie) an der Universität Hamburg mit
dem Prädikat „ausgezeichnet“
11/2004 – 12/2007
Dissertation am Bernhard-Nocht-Institut für Tropenmedizin, Hamburg, in
der Arbeitsgruppe von Prof. Dr. Bernhard Fleischer
10/2004
Diplom; Fächer: Biochemie/Molekularbiologie, Immunologie, Molekulare
Medizin (Gesamtnote: 1,0)
10/1999 – 10/2004
Studium der Biochemie/Molekularbiologie an der Universität Hamburg
07/1998 – 07/1999
Zivildienst im Altenzentrum Springe
08/1985 – 06/1998
Schulausbildung; Abitur (Gesamtnote: 1,0)
Forschungsinteressen:
•
Infektionsimmunologie, angeborenes Immunsystem, C-Typ-Lektine, Adjuvantien
•
Kohlenhydrat-Protein- und Kohlenhydrat-Kohlenhydrat-Interaktionen zum gezielten
Wirkstofftransport
1
Drittmittel:
•
Bundesministerium für Bildung und Forschung (BMBF): „Nachwuchsgruppe Glykobiotechnologie“ (02/2009 – 12/2013); Fkz. 0315446; 921.420,- €
•
Sonderforschungsbereich 765: „Multivalente Kohlenhydrat-Kohlenhydrat-Interaktionen
zum zellspezifischen Targeting und Imaging“ (03/2011 – 12/2015); TP B8; 223.100,- €
•
Bundesministerium für Wirtschaft und Technologie (BMWi): ZIM-Kooperationsprojekt mit
AnalytiCon Discovery, Potsdam: „Entwicklung optimierter partialsynthetischer Saponine
als Adjuvantien“ (10/2011 – 09/2013); Fkz. KF2909301SB1; 175.000,- €
•
Ancora Pharmaceuticals Inc.: „Glykokonjugat-Impfstoffe“; 54.900 US$
Lehrerfahrung:
•
Radiochemie (Praktikum/Seminar), FU Berlin, WS 2009/10 – SS 2012; je 2,5 SWS
•
Glykobiologie/Immunologie (Vorlesung), FU Berlin, seit WS 2010/11; je 1 SWS
•
Immunologie (Praktikum/Seminar), FU Berlin, seit SS 2011; je 2,5 SWS
Stipendien und Auszeichnungen:
•
1. Preis im GKSS-Wettbewerb „Verständliche Wissenschaft“ (2008)
•
Reisestipendien der Deutschen Gesellschaft für Biochemie und Molekularbiologie, der
Europäischen Föderation Immunologischer Gesellschaften (EFIS) und der Bill & Melinda
Gates Stiftung
•
Stipendiat der Studienstiftung des deutschen Volkes (1999-2004)
Mitgliedschaften in wissenschaftlichen Gesellschaften:
•
Deutsche Gesellschaft für Biochemie und Molekularbiologie (GBM, seit 2001)
•
Deutsche Gesellschaft für Immunologie (DGfI, seit 2005)
•
American Chemical Society (ACS, seit 2008)
•
International Endotoxin & Innate Immunity Society (IEIIS, seit 2010)
•
European Macrophage & Dendritic Cell Society (EMDS, seit 2012)
Peer-review Aktivitäten:
•
Reviewer für folgende Stiftungen: Wellcome Trust, Medical Research Council, Minerva
Stiftung, Netherlands Organisation for Scientific Research (NWO), Baden-Württemberg
Stiftung
•
Ad-hoc Reviewer für folgende Journale: ACS Chem. Biol., Bioorg. Med. Chem., Clin.
Vaccine Immunol., Eur. J. Pharm. Biopharm., Int. J. Med. Microbiol., J. Am. Chem. Soc.,
J. Biosci. Bioeng., J. Carbohydr. Chem., J. Mol. Recognit., J. Proteome Res., Med.
Microbiol. Immunol., PLoS One, Proteomics, Small
•
Mitglied im Editorial Board des Journal of Glycomics & Lipidomics
•
Mitarbeit in der Auswahlkommission der Studienstiftung des deutschen Volkes
•
Assoziiertes Mitglied der IMPRS-Fakultät „Multiscale Biosystems“, Potsdam
2
Zusätzliche Qualifikationen:
•
Projektleiter für gentechnische Arbeiten (S1, S2) gemäß §14, §15 GenTSV
•
Erlaubnis zum Umgang mit Krankheitserregern gemäß §44 IfSG
•
Tierversuchsleiter (FELASA-Kurse B, C) gemäß §9 TierSchG
3
Publikationsliste:
Peer-reviewed Artikel:
1. B. Lepenies, I. Gaworski, S. Tartz, J. Langhorne, B. Fleischer, T. Jacobs: CTLA-4
blockade differentially influences the outcome of non-lethal and lethal Plasmodium yoelii
infections. Microbes Infect. 2007; 9(6): 687-94.
2. B. Lepenies, K. Pfeffer, M.A. Hurchla, T.L. Murphy, K.M. Murphy, J. Oetzel, B. Fleischer,
T. Jacobs: Ligation of B and T lymphocyte attenuator prevents the genesis of
experimental cerebral malaria. J. Immunol. 2007; 179(6): 4093-100.
3. B. Lepenies, J.P. Cramer, G.D. Burchard, H. Wagner, C.J. Kirschning, T. Jacobs:
Induction of experimental cerebral malaria is independent of TLR2/4/9. Med. Microbiol.
Immunol. 2008; 197(1): 39-44.
4. J.P. Cramer°, B. Lepenies°, F. Kamena, C. Hölscher, M.A. Freudenberg, G.D. Burchard,
H. Wagner, C.J. Kirschning, X. Liu, P.H. Seeberger, T. Jacobs: MyD88/IL-18-dependent
pathways rather than TLRs control early parasitaemia in non-lethal Plasmodium yoelii
infection. Microbes Infect. 2008; 10(12-13): 1259-65.
°contributed equally
5. S. Boonyarattanakalin, X. Liu, M. Michieletti, B. Lepenies, P.H. Seeberger: Chemical
synthesis of all phosphatidylinositol mannoside (PIM) glycans from Mycobacterium
tuberculosis. J. Am. Chem. Soc. 2008; 130(49): 16791-16799.
6. R. Kikkeri, B. Lepenies, A. Adibekian, P. Laurino, P.H. Seeberger: In vitro imaging and in
vivo liver targeting with carbohydrate capped quantum dots. J. Am. Chem. Soc. 2009;
131(6): 2110-12.
7. G.J. Bernardes, R. Kikkeri, M. Maglinao, P. Laurino, M. Collot, S.Y. Hong, B. Lepenies,
P.H. Seeberger: Design, synthesis and biological evaluation of carbohydratefunctionalized cyclodextrins and liposomes for hepatocyte-specific targeting. Org.
Biomol. Chem. 2010; 8(21): 4987-96.
8. R. Gentsch, F. Pippig, K. Nilles, P. Theato, R. Kikkeri, M. Maglinao, B. Lepenies, P.H.
Seeberger, H.G. Börner: Modular approach towards bioactive fiber meshes carrying
oligosaccharides. Macromolecules 2010; 43(22): 9239-47.
9. D. Grünstein, M. Maglinao, R. Kikkeri, M. Collot, K. Barylyuk, B. Lepenies, F. Kamena,
R. Zenobi, P.H. Seeberger: Hexameric supramolecular scaffold orients carbohydrates to
sense bacteria. J. Am Chem. Soc. 2011; 133(35): 13957-66.
10. S. Khil’chenko, T. Zaporozhets, N. Shevchenko, T. Zvyagintseva, P.H. Seeberger,
B. Lepenies*: Immunostimulatory activity of fucoidan from the brown alga Fucus
evanescens: role of sulfates and acetates. J. Carbohydr. Chem. 2011; 30: 291-305.
11. M.K. Schlegel, J. Hütter, M. Eriksson, B. Lepenies, PH. Seeberger: Defined presentation
of carbohydrates on a duplex DNA scaffold. Chembiochem 2011; 12(18): 2791-800.
12. C.C. Williams, S.H. Thang, T. Hantke, U. Vogel, P.H. Seeberger, J. Tsanaktsidis*,
B. Lepenies*: RAFT-derived polymer-drug conjugates: poly(hydroxypropyl methacrylamide) (HPMA)-7-ethyl-10-hydroxycamptothecin (SN-38) conjugates. ChemMedChem
2012; 7(2): 281-91.
13. J. Hütter, J.V. Rödig, D. Höper, U. Reichl, P.H. Seeberger, E. Rapp*, B. Lepenies*:
Toward animal cell culture-based influenza vaccine design: viral hemagglutinin Nglycosylation markedly impacts immunogenicity. J. Immunol. 2013, 190(1): 220-30.
14. N. Karton-Lifshin, U. Vogel, E. Sella, P.H. Seeberger, D. Shabat*, B. Lepenies*: Enzyme
mediated nutrient release: glucose-precursor activation by β-galactosidase to induce
bacterial growth. Org. Biomol. Chem. 2013, 11(17): 2903-10.
4
15. K. Shirato, C. Gao, F. Ota, T. Angata, H. Shogomori, K. Ohtsubo, K. Yoshida,
B. Lepenies, N. Taniguchi: Flagellin/Toll-like receptor 5 response was specifically attenuated by keratan sulfate disaccharide via decreased EGFR phosphorylation in normal
human bronchial epithelial cells. BBRC 2013, 435(3): 460-65.
16. M. Maglinao, R. Klopfleisch, P.H. Seeberger, B. Lepenies*: The C-type lectin receptor
DCIR is crucial for the development of experimental cerebral malaria. J. Immunol. 2013,
191(5), 2551-59.
17. M. Eriksson, T. Johannssen, D. von Smolinski, A.D. Gruber, P. Seeberger, B. Lepenies*:
The C-type lectin receptor SIGNR3 binds to fungi present in commensal microbiota and
influences immune regulation in experimental colitis. Front. Immunol. 2013, 4, 196.
18. M. Maglinao, M. Eriksson, M.K. Schlegel, S. Zimmermann, T. Johannssen, S. Götze,
P.H. Seeberger, B. Lepenies*: A platform to screen for C-type lectin receptor-binding
carbohydrates and their potential for cell-specific targeting and immune modulation.
J. Control. Release. 2014, 175, 36-42.
19. M. Eriksson, S. Serna, M. Maglinao, M.K. Schlegel, P.H. Seeberger, N.C. Reichardt*,
B. Lepenies*: Biological evaluation of multivalent Lewis X-MGL-1 interactions.
ChemBioChem 2014, im Druck.
20. S.M. Miltsch, P.H. Seeberger, B. Lepenies*: The C-type lectin-like domain containing
proteins Clec-39 and Clec-49 are crucial for Caenorhabditis elegans immunity against
Serratia marcescens infection. Eingereicht.
*corresponding author
Perspectives & Reviews:
1. B. Lepenies, T. Jacobs: The role of negative costimulators during parasitic infections.
Endocr. Metab. Immune Disord. Drug Targets 2008, 8(4): 279-88.
2. P. Stallforth, B. Lepenies, A. Adibekian, P. Seeberger: Carbohydrates: a frontier in
medicinal chemistry. J. Med. Chem. 2009, 52(18): 5561-77.
3. B. Lepenies*, P.H. Seeberger*: The promise of glycomics, glycan arrays and
carbohydrate-based vaccines. Immunopharmacol. Immunotoxicol. 2010, 32(2): 196-207.
4. B. Lepenies, J. Yin, P.H. Seeberger: Applications of synthetic carbohydrates to chemical
biology. Curr. Opin. Chem. Biol. 2010, 14(3): 404-11.
5. D. Kolarich, B. Lepenies, P.H. Seeberger: Glycomics, glycoproteomics and the immune
system. Curr. Opin. Chem. Biol. 2012, 16(1-2): 214-20.
6. B. Lepenies*, J. Lee, S. Sonkaria*: Targeting C-type lectin receptors with multivalent
carbohydrate ligands. Adv. Drug. Deliv. Rev. 2013, 65(9): 1271-81.
Patente:
1. P.H. Seeberger, S. Boonyarattanakalin, B. Lepenies: Chemical synthesis of phosphatidylinositol mannoside glycans from Mycobacterium tuberculosis. WO2010/051961-A1,
2010.
5
Eingeladene Vorträge:
1. B. Lepenies: “Targeting of C-type lectin receptors to modulate immune responses.”
Inaugural Meeting of the Glycosylation and Disease Subgroup of the Euroglycoscience
Forum, Dublin, Irland, 10./11.08.2010.
2. B. Lepenies, P.H. Seeberger: “Automated Oligosaccharide Synthesis, Glycan Arrays and
Nanoparticles as Tools to Understand Infectious Diseases.” Charles Warren Workshop
on Glycoconjugate Analysis, Göteborg, Schweden, 27.-30.08.2010.
3. B. Lepenies: “C-type lectin receptors as targets for immune intervention.” 5th Glycan
Forum, Berlin, 10.-12.03.2011.
4. B. Lepenies: “A platform towards carbohydrate-based immunomodulators”. RIKEN–Max
Planck Joint Meeting, Dortmund, 05.-07.03.2012.
5. B. Lepenies: “A novel platform towards carbohydrate-based adjuvants”. 6th Glycan
Forum, Berlin, 19.-21.03.2012.
6. B. Lepenies: “Towards novel adjuvants: from glycan arrays to murine studies”. 10th
Jenner Glycobiology and Medicine Symposium, Den Haag, Niederlande, 31.03.03.04.2012.
7. B. Lepenies: “Immunomodulators on surfaces: glycan arrays as tools for adjuvant
development”. Dwek Research School of Chemical Science Symposium “From
Molecules to Materials: Advances and Challenges”, Rehovot, Israel, 15./16.07.2012.
8. B. Lepenies: “Searching for C-type lectin receptor ligands: from glycan arrays to murine
studies”. Workshop “Increasing the Impact of Glycoscience through New Tools and
Technology”, San Sebastian, Spanien, 19.-21.07.2012.
9. B. Lepenies: “C-type lectin receptors as targets for immune modulation: from glycan
arrays to murine studies”. Minerva Symposium: The Biophysics of Cells and Tissues,
Potsdam, 24.-26.10.2012.
10. B. Lepenies: “Towards novel carbohydrate-based adjuvants and immunomodulators:
from glycan arrays to murine studies”. Zwischentreffen des Lebenswissenschaftlichen
Kollegs der Studienstiftung des deutschen Volkes, Heidelberg, 15.-17.02.2013.
11. B. Lepenies: “Towards novel carbohydrate-based adjuvants and immunomodulators:
from glycan arrays to murine studies”. Erlangen Center for Infection Research, Erlangen,
07.03.2013.
12. B. Lepenies: “C-type lectin receptors as targets for immune modulation: from glycan
arrays to murine studies”. FResHU F3 Green Symposia Series, Hokkaido University,
Sapporo, Japan, 12.04.2013.
13. B. Lepenies: “Oligosaccharide synthesis & glyco-nanotechnology as tools to understand
carbohydrate-protein interactions”. Natl. University of Mongolia, Ulaanbaatar, Mongolia,
02.07.2013.
14. B. Lepenies: “C-type lectin receptors as targets for immune modulation: from glycan
arrays to murine studies”. Herbsttagung der Deutschen Gesellschaft für Biochemie und
Molekularbiologie (GBM), Frankfurt, 03.-06.10.2013.
15. B. Lepenies: “C-type lectin receptors as targets for immune modulation in infection and
inflammation”. Berlin Parasitology Seminars, Berlin, 12.11.2013.
16. B. Lepenies: “C-type lectin receptor targeting for immune modulation in infection and
inflammation”. Joint Seminar Series of the IRTG 1566 & SFB-TR 84, Berlin, 28.01.2014.
6
17. B. Lepenies: “C-type lectin receptors as targets for immune modulation in infection and
inflammation”. MPI-India joint workshop “Chemical biology of infectious diseases”, New
Delhi, India, 20./21.01.2014.
18. B. Lepenies: “The role of C-type lectin receptors in infection and inflammation". 9th
International Symposium on Glycosyltransferases (GLYCO-T 2014), Porto, Portugal,
18.-21.06.2014.
Konferenzbeiträge (Vorträge):
1. B. Lepenies et al.: “CTLA-4 blockade in malaria: Differential outcome of non-lethal and
lethal Plasmodium yoelii infections”. 28th Conference of Northern German
Immunologists, Borstel 18.11.2005.
2. B. Lepenies et al.: “BTLA is induced and functionally involved in T cell regulation during
murine malaria”. 16th European Congress of Immunology, Paris, Frankreich, 06.09.09.2006.
3. B. Lepenies et al.: “Ligation of B and T lymphocyte attenuator (BTLA) prevents the
genesis of experimental cerebral malaria”. 13th International Congress of Immunology,
Rio de Janeiro, Brasilien, 21.-25.08.2007.
4. B. Lepenies et al.: “Recognition of plasmodial GPI analogues depends on TLR2 and
MyD88 while only MyD88 is essential for protection from malaria”. 13th International
Congress of Immunology, Rio de Janeiro, Brasilien, 21.-25.08.2007.
5. B. Lepenies et al.: “Toll-like receptor cascade in murine malaria: Role of TLR2/4/9 in
protection and pathology”. Annual fall meeting of the German Society for Biochemistry
and Molecular Biology, Hamburg, 16.-19.09.2007.
6. B. Lepenies et al.: “Ligation of B and T lymphocyte attenuator (BTLA) protects mice from
cerebral malaria during P. berghei ANKA infection.” Annual Keystone Meeting “Malaria:
Immunology, Pathogenesis and Vaccine Perspectives”, Alpbach, Österreich, 08.13.06.2008.
7. B. Lepenies: “Role of C-type lectin receptors in infection and autoimmunity.” LiseMeitner-Kolloquium of the Free University, Berlin, 08.05.2009.
8. B. Lepenies: “Targeting of C-type lectin receptors to modulate immune responses.”
Symposium BMBF-geförderter Nachwuchsgruppenleiter, Berlin, 26./27.01.2010.
9. B. Lepenies et al.: “Novel tools in immunology: Sugar-capped nanoparticles for cellspecific targeting.” 33rd Symposium of North-German Immunologists “Challenges in
Immunology”, Borstel, 12.11.2010.
10. B. Lepenies et al.: “Targeting C-type lectin receptors with synthetic carbohydrates to
modulate immune responses.” GLYCO 21, Wien, Österreich, 21.-26.08.2011.
11. B. Lepenies et al.: “Influenza A virus hemagglutinin N-glycosylation strongly impacts
immunogenicity”. 26th International Carbohydrate Symposium, Madrid, Spanien, 22.26.07.2012.
12. B. Lepenies et al.: “The C-type lectin receptor DCIR is involved in the genesis of cerebral
malaria”. Jahrestagung der Deutschen Gesellschaft für Immunologie (DGfI), Mainz, 11.14.09.2013.
7
Konferenzbeiträge (Poster):
1. B. Lepenies, S. Boonyarattanakalin, X. Liu, R. Kikkeri, A. Adibekian, P. Laurino, P.H.
Seeberger: “Cell-specific drug delivery by targeting of C-type lectin receptors using
synthetic carbohydrate ligands.” 9th World Congress on Inflammation, Tokio, Japan, 06.10.07.2009.
2. B. Lepenies, S. Boonyarattanakalin, X. Liu, R. Kikkeri, A. Adibekian, P. Laurino, P.H.
Seeberger: “Specific Targeting of C-Type Lectin Receptors Utilizing Synthetic
Carbohydrate Ligands.” 2nd European Congress of Immunology, Berlin, 13.-16.09.2009.
3. S.Y. Hong, R. Kikkeri, M. Collot, M. Maglinao, B. Lepenies, P.H. Seeberger: “GlycoDendrimers for Lectin Dimerization.” NanoBio, Zürich, Schweiz, 24.-27.08.2010.
4. D. Esposito, R. Kikkeri, M. Eriksson, B. Castagner, B. Lepenies, P.H. Seeberger:
“Exploiting Carbohydrate-Carbohydrate Interactions for In Vitro Imaging of Melanoma
cells.” Sialoglyco Meeting, Potsdam, 21.-26.08.2010.
5. M. Janßen, R. Ebbeler, B. Lepenies, C. Hölscher, B. Fleischer, T. Jacobs: “Effects of
Th1 based versus Th17 based immune responses on cerebral malaria.” 40th Annual
Meeting of the German Society for Immunology, Leipzig, 22.-25.09.2010.
6. M. Maglinao, M. Eriksson, M. Irgang, P.H. Seeberger, B. Lepenies: “Targeting of C-Type
Lectin Receptors to Modulate Immune Responses.” 33rd Symposium of North-German
Immunologists, Borstel, 12.11.2010.
7. M. Eriksson, D. Esposito, R. Kikkeri, B. Castagner, B. Lepenies, P.H. Seeberger:
“Imaging of Carbohydrate Biomarkers on Cancer Cells by Using CarbohydrateCarbohydrate Interactions.” 33rd Symposium of North-German Immunologists, Borstel,
12.11.2010.
8. M. Schlegel, J. Hütter, B. Lepenies, P.H. Seeberger: “Targeting of murine MGL using
synthetic DNA-carbohydrate conjugates.” 33rd Symposium of North-German
Immunologists, Borstel, 12.11.2010.
9. M. Maglinao, M. Eriksson, M. Irgang, P.H. Seeberger, B. Lepenies: “Probing C-type
lectin-carbohydrate interactions using microarrays of synthetic oligosaccharides.”
Keystone Symposium “New Frontiers at the Interface of Immunity and Glycobiology”,
Lake Louise, Kanada, 06.-11.03.2011.
10. J. Hütter, J. Rödig, U. Reichl, P.H. Seeberger, E. Rapp, B. Lepenies: “Impact of
Influenza A virus hemagglutinin N-glycosylation on immunogenicity.” 5th Glycan Forum,
Berlin, 10.-12.03.2011.
11. M. Eriksson, M. Maglinao, M. Irgang, P.H. Seeberger, B. Lepenies: “Analysis of the role
of C-type lectin receptors and their carbohydrate ligands in inflammatory processes.” 5th
Glycan Forum, Berlin, 10.-12.03.2011.
12. M. Eriksson, D. Esposito, H.S. Hahm, R. Kikkeri, B. Castagner, B. Lepenies, P.
Seeberger: “Carbohydrate-capped quantum dots as a tool for in vitro imaging of the
gangliosides GM3 and Gg3.” 5th Glycan Forum, Berlin, 10.-12.03.2011.
13. S.R. Khil’chenko, T.S. Zaporozhets, N.M. Shevchenko, P.H. Seeberger, B. Lepenies:
“Immunostimulatory function of native and chemically modified fucoidan from the brown
alga Fucus evanescens.” 5th Glycan Forum, Berlin, 10.12.03.2011.
14. J. Hütter, J. Rödig, U. Reichl, P.H. Seeberger, E. Rapp, B. Lepenies: “Impact of
Influenza A virus hemagglutinin N-glycosylation on immunogenicity.” GLYCO 21, Wien,
Österreich, 21.-26.08.2011.
15. M. Eriksson, M. Maglinao, M. Irgang, M.K. Schlegel, P.H. Seeberger, B. Lepenies: “A
platform to screen for the immune modulatory properties of C-type lectin binding
8
carbohydrates.” Keystone Symposium “Innate Immunity: Sensing the Microbes and
Damage Signals”, Keystone, CO, USA, 04.-09.03.2012.
16. N. Zimara, M. Schmidt, D. Maennel, B. Lepenies, U. Ritter: “The impact of C-type lectins
on the course of experimental leishmaniasis.” 16th Symposium „Infection and Immunity“,
Burg Rothenfels, 08.-10.03.2012.
17. M. Eriksson, M. Maglinao, M.K. Schlegel, C. Anish, P.H. Seeberger, B. Lepenies: “A
novel platform to screen for carbohydrate-based adjuvants and immunomodulators.”
European Congress of Immunology, Glasgow, UK, 05.-08.09.2012. Published in:
Immunology 2012, 137 (Suppl. 1), 654-55.
18. J. Hütter, J. Rödig, D. Höper, U. Reichl, P.H. Seeberger, E. Rapp, B. Lepenies:
“Glycosylation matters: role of viral hemagglutinin N-glycosylation in immunogenicity.”
European Congress of Immunology, Glasgow, UK, 05.-08.09.2012. Published in:
Immunology 2012, 137 (Suppl. 1), 760-61.
19. M. Maglinao, R. Klopfleisch, P.H. Seeberger, B. Lepenies: “Role of the C-type lectin
receptor DCIR in cerebral malaria development.” European Congress of Immunology,
Glasgow, UK, 05.-08.09.2012. Published in: Immunology 2012, 137 (Suppl. 1), 310.
20. J. Hütter, P. Seeberger, B. Lepenies: “Multivalent carbohydrate/lectin and carbohydrate/
carbohydrate interactions for cell-specific targeting and imaging.” 2nd International
Symposium of the Collaborative Research Center (SFB) 765, Berlin, 18./19.10.2012.
21. M. Eriksson, T. Johannssen, D. von Smolinski, A. Gruber, P.H. Seeberger, B. Lepenies:
“The C-type lectin receptor SIGNR3 binds to commensal microbiota and influences
immune regulation in experimental colitis.” 7th Glycan Forum, Berlin, 20.-22.03.2013.
22. S.M. Miltsch, P.H. Seeberger, B. Lepenies: “Role of C-type lectins in Caenorhabditis
elegans.” 7th Glycan Forum, Berlin, 20.-22.03.2013.
23. S. Zimmermann, T. Johannssen, P. Seeberger, B. Lepenies: “Generation and functional
characterization of a Mincle-Fc fusion protein.” 7th Glycan Forum Berlin, 20.-22.03.2013.
24. M. Maglinao, R. Klopfleisch, P.H. Seeberger, B. Lepenies: “The C-type lectin receptor
DCIR is involved in the genesis of cerebral malaria.” RIKEN–Max Planck Joint Meeting,
Wako, 15.-17.04.2013.
25. M. Eriksson, T. Johannssen, D. von Smolinski, A. Gruber, P.H. Seeberger, B. Lepenies:
“The C-type lectin receptor SIGN-R3 binds to commensal microbiota and influences
immune regulation in experimental colitis.” 15th International Congress of Immunology,
Mailand, Italien, 22.-27.08.2013.
Berlin, den 13.01.2014
9